Cargando…
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and bone loss. However, the precise effects of this switch on the blood lipid profile remain to be clarified. This is an impor...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775237/ https://www.ncbi.nlm.nih.gov/pubmed/35051189 http://dx.doi.org/10.1371/journal.pone.0261760 |
_version_ | 1784636537175015424 |
---|---|
author | Suzuki, Kazuharu Suda, Goki Yamamoto, Yoshiya Abiko, Satoshi Kinoshita, Kenji Miyamoto, Shuichi Sugiura, Ryo Kimura, Megumi Maehara, Osamu Yamada, Ren Kitagataya, Takashi Shigesawa, Taku Ohara, Masatsugu Kawagishi, Naoki Nakai, Masato Sho, Takuya Natsuizaka, Mitsuteru Morikawa, Kenichi Ogawa, Koji Sakamoto, Naoya |
author_facet | Suzuki, Kazuharu Suda, Goki Yamamoto, Yoshiya Abiko, Satoshi Kinoshita, Kenji Miyamoto, Shuichi Sugiura, Ryo Kimura, Megumi Maehara, Osamu Yamada, Ren Kitagataya, Takashi Shigesawa, Taku Ohara, Masatsugu Kawagishi, Naoki Nakai, Masato Sho, Takuya Natsuizaka, Mitsuteru Morikawa, Kenichi Ogawa, Koji Sakamoto, Naoya |
author_sort | Suzuki, Kazuharu |
collection | PubMed |
description | For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and bone loss. However, the precise effects of this switch on the blood lipid profile remain to be clarified. This is an important issue as TDF is known to have effects on both low- and high-density lipids. Therefore, our retrospective multi-center study aimed to evaluate the effects of switching from TDF to TAF on the lipid profile of patients with HBV infection. Samples were obtained prior to the switch from TDF to TAF and at 6–12 months after TAF initiation. In some cases, additional samples obtained pre- and post-TDF administration were available for analysis. Serum cholesterol levels, including oxidized-low-density lipoprotein (LDL) and non-high-density lipoprotein-cholesterol (HDL-c), and the rate of dyslipidemia, according to the NCEP-ATP III lipid risk classification, were analyzed. The data from 69 patients were analyzed, including 33 patients with pre- and post-TDF-initiation serum samples. Total cholesterol (T-chol), HDL-c, LDL-c, non-HDL-c, and oxidized LDL levels increased significantly after switching to TAF. With regard to sequential changes pre- to post-TAF, TDF was associated with significantly lower serum T-chol, HDL-c, and oxidized LDL-c levels, with T-chol, HDL-c, LDL-c, and oxidized LDL-c levels increasing significantly after the switch. The switch from TDF to TAF was also associated with an increase in the rate of dyslipidemia, from 33% to 39%, with an increase in the rate of severe dyslipidemia of 1.4% and 5.8%, based on T-chol and LDL-c levels. Of note, no cases of severe dyslipidemia were detected pre-TAF treatment. As oxidized LDL-c and non-HDL-c are strongly associated with atherosclerosis development, careful monitoring of lipid is needed after switching from TDF to TAF in this clinical population. |
format | Online Article Text |
id | pubmed-8775237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-87752372022-01-21 Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B Suzuki, Kazuharu Suda, Goki Yamamoto, Yoshiya Abiko, Satoshi Kinoshita, Kenji Miyamoto, Shuichi Sugiura, Ryo Kimura, Megumi Maehara, Osamu Yamada, Ren Kitagataya, Takashi Shigesawa, Taku Ohara, Masatsugu Kawagishi, Naoki Nakai, Masato Sho, Takuya Natsuizaka, Mitsuteru Morikawa, Kenichi Ogawa, Koji Sakamoto, Naoya PLoS One Research Article For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and bone loss. However, the precise effects of this switch on the blood lipid profile remain to be clarified. This is an important issue as TDF is known to have effects on both low- and high-density lipids. Therefore, our retrospective multi-center study aimed to evaluate the effects of switching from TDF to TAF on the lipid profile of patients with HBV infection. Samples were obtained prior to the switch from TDF to TAF and at 6–12 months after TAF initiation. In some cases, additional samples obtained pre- and post-TDF administration were available for analysis. Serum cholesterol levels, including oxidized-low-density lipoprotein (LDL) and non-high-density lipoprotein-cholesterol (HDL-c), and the rate of dyslipidemia, according to the NCEP-ATP III lipid risk classification, were analyzed. The data from 69 patients were analyzed, including 33 patients with pre- and post-TDF-initiation serum samples. Total cholesterol (T-chol), HDL-c, LDL-c, non-HDL-c, and oxidized LDL levels increased significantly after switching to TAF. With regard to sequential changes pre- to post-TAF, TDF was associated with significantly lower serum T-chol, HDL-c, and oxidized LDL-c levels, with T-chol, HDL-c, LDL-c, and oxidized LDL-c levels increasing significantly after the switch. The switch from TDF to TAF was also associated with an increase in the rate of dyslipidemia, from 33% to 39%, with an increase in the rate of severe dyslipidemia of 1.4% and 5.8%, based on T-chol and LDL-c levels. Of note, no cases of severe dyslipidemia were detected pre-TAF treatment. As oxidized LDL-c and non-HDL-c are strongly associated with atherosclerosis development, careful monitoring of lipid is needed after switching from TDF to TAF in this clinical population. Public Library of Science 2022-01-20 /pmc/articles/PMC8775237/ /pubmed/35051189 http://dx.doi.org/10.1371/journal.pone.0261760 Text en © 2022 Suzuki et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Suzuki, Kazuharu Suda, Goki Yamamoto, Yoshiya Abiko, Satoshi Kinoshita, Kenji Miyamoto, Shuichi Sugiura, Ryo Kimura, Megumi Maehara, Osamu Yamada, Ren Kitagataya, Takashi Shigesawa, Taku Ohara, Masatsugu Kawagishi, Naoki Nakai, Masato Sho, Takuya Natsuizaka, Mitsuteru Morikawa, Kenichi Ogawa, Koji Sakamoto, Naoya Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B |
title | Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B |
title_full | Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B |
title_fullStr | Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B |
title_full_unstemmed | Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B |
title_short | Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B |
title_sort | effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis b |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775237/ https://www.ncbi.nlm.nih.gov/pubmed/35051189 http://dx.doi.org/10.1371/journal.pone.0261760 |
work_keys_str_mv | AT suzukikazuharu effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT sudagoki effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT yamamotoyoshiya effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT abikosatoshi effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT kinoshitakenji effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT miyamotoshuichi effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT sugiuraryo effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT kimuramegumi effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT maeharaosamu effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT yamadaren effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT kitagatayatakashi effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT shigesawataku effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT oharamasatsugu effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT kawagishinaoki effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT nakaimasato effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT shotakuya effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT natsuizakamitsuteru effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT morikawakenichi effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT ogawakoji effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb AT sakamotonaoya effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb |